Milestones

MOVETIS is committed to developing and ultimately commercializing new therapeutics for the treatment of a variety of gastrointestinal (GI) disorders where only limited or inadequate alternatives are currently available.

Using the initial series ‘A’ funding, MOVETIS will perform the following critical activities:

• finalize the required CMC work and prepare RESOLOR for filing by beginning of 2009
• generate conclusive phase II data for M0002 in ascites
• further develop our two most advanced prokinetic candidates (M0003 & M0004) and enter phase II development
• enter clinical development with one currently preclinical compound and generate a lead compound from the cGKII or 5HT discovery program